Russia says it developed COVID-19 treatment based on anti-malaria drug

Russia's Federal Biomedical Agency on Saturday said it has built up a medication for the treatment of COVID-19.

The organization said its medication depended on mefloquine, which is utilized to forestall or treat jungle fever.

The medication will purportedly give viable treatment to COVID-19 patients with fluctuating seriousness.

As indicated by the office's announcement, the medication forestalls infection replication in cells and accordingly, stops the provocative procedure brought about by the infection.

Veronika Skvortsova, the organization's head, said Mefloquine must be joined with anti-infection agents for the greatest impact, permitting an expansion in the convergence of antiviral operators in blood plasma and lungs.

This will guarantee powerful treatment of patients with different degrees of coronavirus contamination, Skvortsova said.


The organization said it was building up a successful and safe plan for the counteraction of coronavirus based on mefloquine.

The treatment was created considering Chinese and French understanding, it included.

COVID-19 treatment, for the present, centers around alleviating indications, for example, breathing help.

Organizations around the globe are dashing to create antibodies. A couple have propelled early wellbeing testing in people, however specialists state it could take a year or more to create and test an antibody.